Table 1 Patient characteristics for primary or recurrent ovarian cancer who underwent ureteral reconstruction
Characteristics | Total | Primary | Recurrent |
|---|---|---|---|
N = 56 (%) | N = 35 (62.5%) | N = 21 (37.5%) | |
Median Age at diagnosis, years (range) | 54 (18–73) | 52 (39–73) | 51 (18–73) |
BMI, kg/m2 (range) | 22.3 (16.2–31.7) | 20.1 (16.4–31.7) | 21.8 (16.2–29.7) |
ECOG performance status | |||
0–1 | 54 (96.4) | 34 (97.1) | 20 (95.2) |
2 | 2 (3.6) | 1 (2.9) | 1 (4.8) |
Stage (FIGO 2014)a | |||
I | 7 (12.5) | 6 (17.1) | 1 (4.8) |
II | 7 (12.5) | 4 (11.4) | 3 (14.3) |
III | 33 (58.9) | 20 (57.1) | 13 (61.9) |
IV | 9 (16.1) | 5 (14.3) | 4 (19.0) |
Histology | |||
High grade serous | 27 (48.2) | 18 (51.4) | 9 (42.9) |
Endometrioid | 7 (12.5) | 6 (17.1) | 2 (9.5) |
Clear cell | 7 (12.5) | 4 (11.4) | 3 (14.3) |
Mucinous | 2 (3.6) | 1 (2.9) | 2 (9.5) |
Neuroendocrine carcinoma | 1 (1.8) | 1 (2.9) | 0 (0) |
Granulosa cell tumor | 3 (5.4) | 1 (2.9) | 2 (9.5) |
Carcinosarcoma | 3 (5.4) | 1 (2.9) | 2 (9.5) |
Others | 5 (8.9) | 3 (8.6) | 2 (9.5) |
Neoadjuvant chemotherapy | |||
No | 48 (85.7) | 27 (77.1) | 21 (100) |
Yes | 8 (14.3) | 8 (22.9) | 0 (0) |
Previous radiotherapy | |||
No | 55 (98.2) | 35 (100) | 20 (95.2) |
Yes | 1 (1.8) | 0 (0) | 1 (4.8) |
Previous chemotherapy | |||
No | 34 (60.7) | 32 (91.4) | 2 (9.5) |
Yes | 22 (39.3) | 3 (8.6) | 19 (90.5) |